Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared on X:
“An 8.5-month OS gain after EGFR-TKI failure!
At ESMO26, Prof. Wenfeng Fang presented final Phase III OptiTROPLung04 results in EGFR-mutant NSCLC.
Sac-TMT vs chemotherapy:
OS: 25.9 vs 17.4 months
HR 0.69
A potential practice-changing ADC milestone.”
Read more articles featuring Ahmet Dirican on OncoDaily.
You may also be interested in: SAFFRON Phase III: Osimertinib Plus Savolitinib Significantly Improves Progression-Free and Overall Survival in MET-Driven EGFR-Mutated NSCLC
